Helgran 75 WG Polonia - poloneză - Ministerstwo Rolnictwa i Rozwoju Wsi

helgran 75 wg

helm ag nordkanalstrasse, d-20097 hamburg, republika federalna niemiec - tribenuron metylu - tribenuron metylu - 750 g - chwastobójczy

Rebetol Uniunea Europeană - poloneză - EMA (European Medicines Agency)

rebetol

merck sharp and dohme b.v - rybawiryna - wirusowe zapalenie wątroby typu c, przewlekłe - antivirals for systemic use, antivirals for treatment of hcv infections - rebetol jest wskazany w skojarzeniu z innymi produktami leczniczymi stosowanymi w leczeniu przewlekłego wirusowego zapalenia wątroby typu c (chc) u dorosłych. Ребетол podano w połączeniu z innymi lekami do leczenia przewlekłego wirusowego zapalenia wątroby typu c (hcv) dla pediatrycznych pacjentów (dzieci od 3 lat i starsze oraz młodzież) nie wcześniej korzystały z i bez dekompensacji wątroby.

Kaftrio Uniunea Europeană - poloneză - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Kalydeco Uniunea Europeană - poloneză - EMA (European Medicines Agency)

kalydeco

vertex pharmaceuticals (ireland) limited - iwakaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.